A Phase 1b Study of SAR650984 (Isatuximab) in Combination With Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Trial Profile

A Phase 1b Study of SAR650984 (Isatuximab) in Combination With Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Isatuximab (Primary) ; Dexamethasone; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms PomdeSAR
  • Sponsors Sanofi
  • Most Recent Events

    • 22 Mar 2018 Planned End Date changed from 19 Aug 2020 to 23 Aug 2020.
    • 22 Mar 2018 Planned primary completion date changed from 19 Aug 2020 to 23 Aug 2020.
    • 12 Dec 2017 Updated results from the study (data cut off: 1 Mar, 2017; n=36), presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top